A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide maintenance therapy for patients with relapsed Multiple Myeloma

Trial Profile

A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide maintenance therapy for patients with relapsed Multiple Myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Ciprofloxacin; Dexamethasone; Low molecular weight heparin; Melphalan; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ReLApsE
  • Most Recent Events

    • 03 Jul 2017 Status changed from recruiting to completed.
    • 06 Oct 2016 Planned End Date changed from 26 Sep 2015 to 30 Jun 2017.
    • 06 Oct 2016 Status changed from completed to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top